The Hedgehog (Hh) signaling pathway is involved in the development of many tissues during embryogenesis, but has also been described to function in adult self-renewing tissues. In the immune system, Sonic Hedgehog (Shh) regulates intrathymic T cell development and modulates the effector functions of peripheral CD4+ T cells. In this study we investigate whether Shh signaling is involved in peripheral B cell differentiation in mice. Shh is produced by follicular dendritic cells, mainly in germinal centers (GCs), and GC B cells express both components of the Hh receptor, Patched and Smoothened. Blockade of the Hh signaling pathway reduces the survival, and consequently the proliferation and Ab secretion, of GC B cells. Furthermore, Shh rescues GC B cells from apoptosis induced by Fas ligation. Taken together, our data suggest that Shh is one of the survival signals provided by follicular dendritic cells to prevent apoptosis in GC B cells.

The Hedgehog (Hh)4 protein family is a group of secreted intercellular signaling molecules that are essential for cell fate and patterning during the development of many organs (1, 2). Hh was first identified in Drosophila (3), and several vertebrate homologues have been subsequently discovered (1). In mammals, three proteins comprise the Hh family: Sonic (Shh), Indian (Ihh), and Desert Hedgehog (Dhh); Shh is the best studied (1).

Hh proteins are synthesized as precursor proteins that undergo an internal cleavage catalyzed by the C-terminal portion of the precursor. This process generates a C-terminal fragment that has no other known function and an N-terminal fragment that has all known signaling activity (4, 5). The biologically active N-terminal fragment receives two lipid modifications, cholesterol coupling and palmitoylation. Both modifications facilitate tethering of the protein to the cell membrane of Hh-synthesizing cells, allowing it to function as a short range signaling molecule with neighboring cells (6, 7, 8). The N-terminal fragment can be also released from Hh-producing cells by the action of Dispatched (9, 10) and is then free to diffuse and exert its long range activity (11, 12, 13, 14).

All Hh proteins share a common signaling pathway, where Patched (Ptc) and Smoothened (Smo) are the membrane receptors. Ptc is the ligand binder, and Smo transduces the signal into the cell. In the absence of ligand, Ptc exerts an inhibitory effect on Smo activity that is abrogated after Hh binding. In the absence of Ptc, Smo is constitutively active (1, 15). The mechanism underlying Ptc’s inhibitory function is under debate, although recent evidence suggests that permanent physical interaction between Ptc and Smo is not necessary. On the contrary, this inhibition involves the regulation of vesicular trafficking and cytoplasmic transport of small molecules that modulate Smo activity (16, 17, 18, 19). Cell surface Ptc expression, in the absence of Smo, may also function to sequester extracellular Hh protein (1, 2).

At the end of the Hh signaling pathway are the members of the Gli family of transcription factors, Gli1, Gli2, and Gli3. The specific functions of the Gli proteins are still unknown, although all the activities demonstrated for Gli1 are positive, whereas Gli2 and Gli3 mainly function as positive and negative regulators of transcription, respectively (20, 21, 22).

Recent studies have revealed that Hh proteins not only determine patterning and cell fate during embryonic development, but also function in cell fate determination of self-renewing tissues in the adult, such as the hemopoietic and immune systems. Shh has been shown to regulate the proliferation and differentiation of human hemopoietic precursor cells (23, 24). In the thymus, Shh signaling plays an important role regulating thymic cellularity as well as the development of CD4CD8 thymocytes (25, 26, 27, 28). In addition, the effector function of peripheral CD4+ T cells is modulated by Shh (29, 30). However, no evidence of a role for Hh signaling in B cell differentiation and function has been described. In this study we analyze the expression of Shh in peripheral lymphoid organs and show that Shh is produced by follicular dendritic cells (FDCs), mainly in germinal centers (GCs). GCs are specialized microenvironments comprised primarily of B cells, FDCs, tingible body macrophages, and some T cells. In the GCs, B cells efficiently undergo clonal expansion, somatic hypermutation, and selection to differentiate into memory B cells capable of producing high affinity Abs or into plasma cells secreting Ig (31, 32, 33, 34). We also report that GC B cells express Hh receptors and that their survival and function are altered after inhibition of the Hh signaling pathway. In addition, Shh protects GC B cells from Fas-induced apoptosis. Our results indicate, therefore, that Shh signaling is involved in the FDC-mediated rescue of GC B cells from apoptosis.

Young adult female BALB/c mice were purchased from Harlan Iberica and maintained under pathogen-free conditions. Mice were immunized s.c. with 100 μg of OVA precipitated in alum or i.p. with 108 SRBC.

Lymph nodes (LNs) and spleens were obtained before and 7–10 days after immunization, embedded in OCT compound (Miles), and frozen in liquid nitrogen. Cryosections (7 μm thick) were air-dried for 2 h at room temperature and fixed in acetone for 10 min. Nonspecific binding of Abs and streptavidin was blocked by incubation with diluted donkey serum (Santa Cruz Biotechnology) and avidin-biotin (Vector Laboratories). Shh protein was detected using specific goat Abs against either the C-terminal fragment of Shh (R&D Systems) or the N-terminal domain of Shh (Santa Cruz Biotechnology), obtaining similar results. Next, tissue sections were sequentially incubated with FITC-conjugated multiadsorbed F(ab′)2 of donkey anti-goat IgG (Jackson ImmunoResearch Laboratories) and anti-FDCs (FDC-M2; AMS Biotechnology) or anti-B220 (BD Biosciences) mAbs, followed by Texas Red-conjugated multiadsorbed F(ab′)2 of donkey anti-rat IgG (Jackson ImmunoResearch Laboratories). In some cases, to detect GCs the sections were also incubated with biotin-conjugated peanut agglutinin (PNA; Sigma España) and streptavidin-conjugated 7-amino-4 methylcoumarin-3 acetic acid (Vector Laboratories). Slides were mounted in Vectashield (Vector Laboratories) and examined on an Axioplan-2 microscope (Zeiss) from the Centro de Microscopía y Citometría, Complutense University of Madrid.

RT-PCR was performed as previously described (26). RNA isolation was performed using a Strataprep Total RNA Miniprep kit (Stratagene), including a DNase I digestion step, as recommended by the supplier, to avoid genomic DNA contamination. Total cDNA was synthesized with Superscript II RT polymerase (Invitrogen Life Technologies). Primers were purchased from Sigma-Genosys. Amplifications were performed using the following primer sets and annealing conditions: Ptc: forward primer, 5′-TGGCCTGCACGTTTCTAGTG-3′; reverse primer, 5′-GCCAGGACGGCAAAGAAGTA-3′ (61°C; 364-bp); and SMO: forward primer, 5′-CCCCAGGATGTGTCCGTTAC-3′; reverse primer, 5′-GGCAGAAGGGGTTGGAGACTA-3′ (61°C; 322 bp). Primers were designed from sequences available from the GenBank database (accession no.: Ptc, XM_008959; Smo, XM_008959). Primers to detect G3PDH and Shh were previously described (29, 35). All PCRs were performed on a MasterCycler gradient machine (Eppendorf) using AmpliTaq Gold DNA polymerase (Applied Biosytems) under the following conditions: 3 min at 94°C, 40 cycles of 45 s at 94°C, 45 s of each particular T annealing, 45 s at 72°C, followed by 10 min at 72°C. PCR products were resolved on a 2% agarose gel, and the expected sizes were measured.

GC cells were isolated from the spleens or LNs of mice 7–10 days after primary immunization with SRBC or OVA, according to the procedure described by Kosco et al. (36). Briefly, after enzymatic digestion with collagenase and DNase I (Sigma España), the low density (1.060–1.065 g/ml) cells were isolated on Percoll (Pharmacia Biotech) gradients, and adherent cells were removed after a 1-h adherence step at 37°C. As previously reported, the resulting population consisted of 75–85% B cells, 5–10% T cells, 5–10% FDCs, and <5% tingible body macrophages (36, 37, 38).

For isolation of GC B cells, GC cell suspensions were stained with anti-B220-PE mAb (BD Biosciences) and purified by magnetic sorting using AutoMACS (Miltenyi Biotec) in conjunction with anti-PE Microbeads (Miltenyi Biotec) according to the manufacturer’s instructions.

To analyze the expression of Ptc and Smo receptors on GC B cells, three- and four-color immunofluorescence stainings were performed by incubating GC cells in PBS containing 1% FCS and 0.1% NaN3 in the presence of saturating amounts of anti-Smo-PE and anti-B220-allophycocyanin Abs and FITC- or biotin-conjugated PNA, followed by streptavidin-Tricolor, for 30 min at 4°C. In some experiments, cells were then treated with a FACS permeabilizing solution according to manufacturer’s instructions (BD Biosciences), stained with anti-Ptc-FITC Ab, recognizing an intracellular domain at the N terminus of Ptc, for 30 min, and fixed (BD Biosciences). In all experiments, unconjugated anti-CD16/32 mAb was also added to the Ab mixture to minimize FcR-dependent background staining. Cells were analyzed in a FACSCalibur (BD Biosciences) from the Centro de Microscopía y Citometría, Complutense University of Madrid. Purified anti-Smo (N-19) and anti-Ptc (G-19) Abs were obtained from Santa Cruz Biotechnology and conjugated to FITC or PE by Biogenesis. Anti-B220-allophycocyanin and anti-CD16/32 mAbs were purchased from BD Biosciences, biotin/FITC-conjugated PNA was obtained from Sigma-Aldrich, and streptavidin-Tricolor was purchased from Caltag Laboratories.

GC cells were cultured in flat-bottom, 96-well plates (2 × 105 cells/well) in RPMI 1640 medium (Invitrogen Life Technologies) supplemented with 5% FCS (Harlan Sera-Lab), 2 mM l-glucagon (Invitrogen Life Technologies), and penicillin/streptomycin (Invitrogen Life Technologies). For B cell stimulation, GC cells were cultured for 4 h with anti-CD40 (5 μg/ml), anti-IgM (5 μg/ml), or LPS (5 μg/ml). For cell proliferation assays, cultures were pulsed with 10 μM BrdU for the last 12 h of the culture period, and BrdU incorporation into newly synthesized DNA was measured using the BrdU Labeling and Detection kit III (Roche) as previously described (39). Briefly, the labeling medium was removed, and cells were dried (2 h at 60°C), fixed in ethanol in HCl (0.5 M) for 30 min at −20°C, treated with nucleases (30 min at 37°C), and then incubated with peroxidase-conjugated Fab of mouse anti-BrdU Abs (30 min at 37°C). The peroxidase reaction was developed with ABTS substrate, and the sample absorbance was measured using an ELISA reader. The Ig production was assayed in day 7 cell culture supernatants using ELISA procedures. Plates were coated with goat anti-mouse IgM, IgG1, IgG2a, IgG2b, or IgG3 (Caltag Laboratories) and developed with HRP-coupled goat anti-IgM+IgG (Caltag Laboratories).

In the proliferation and Ab production experiments, cyclopamine (5 μM) or anti-Shh mAb (20 μg/ml) was added to the cells from the beginning of the cultures. Cyclopamine was a gift from Dr. W. Gaffield (Western Regional Research Center, Albany, CA). The neutralizing anti-Shh mAb 5E1 (40) was obtained from the Developmental Studies Hybridoma Bank, developed under the auspices of the National Institute of Child Health and Human Development and maintained by the University of Iowa (Iowa City, CA).

GC cells were cultured in the absence or the presence of cyclopamine (5 μM) or anti-Shh mAb (20 μg/ml) for 12 h. After cells were stained with anti-B220-allophycocyanin and PNA-biotin plus streptavidin-Tricolor, and washed twice with PBS containing 1% FCS, cells were stained with Annexin VFITC (BD Biosciences) according to the instructions of the manufacturer.

GC B cells were cultured for 12 h with anti-Fas mAb (0.2 μg/ml; BD Biosciences) and in the absence or the presence of modified human Shh (provided by Curis). Shh protein was octylated for high activity. In vitro modification of N-Shh (aa 25–199) with a lipophilic group on the N-terminal cysteine significantly increases the spec. act. (30-fold) of Escherichia coli-derived N-Shh as measured by activation of Hh signal transduction in cultured cells (41). Octyl N-Shh is a hydrophobically modified version of the Shh signaling protein generated by coupling N-octyl-malemide to the N-terminal cysteine of bacterially derived N-Shh. In some experiments anti-CD40 (BD Biosciences) and anti-IgM (Jackson ImmunoResearch Laboratories) Abs were used at 5 μg/ml. Cells were then stained with PNA-biotin plus streptavidin-Tricolor and Annexin VFITC.

Analyses were conducted on a FACSCalibur (BD Biosciences), and cells were gated according to forward and side scatter and their ability to exclude propidium iodide. Apoptotic cells were considered as those annexin V-positive and propidium iodide-negative.

The expression of Shh was studied on sections of murine secondary lymphoid organs. Shh was highly expressed in GCs of LNs and spleen from immunized mice. Interestingly, Shh expression was associated with the reticulum formed by FDC-M2-positive FDCs appearing in the light zone (Fig. 1, A–D). The double labeling of tissue sections with anti-Shh and anti-B220 Abs did not show the existence of overlapping areas, indicating that B lymphocytes do not express Shh in GCs (Fig. 1,E). To further investigate the expression of Shh in the FDC network found in primary follicles, an identical histological analysis was performed in LNs and spleen obtained from unimmunized mice housed in specific pathogen free-conditions. In contrast to the FDC network of GCs, only a few FDCs expressed Shh in the primary follicles (Fig. 1, F and G). Similarly, in CD28-deficient mice, which are unable to form GCs (42), a low number of FDCs weakly expressed Shh (data not shown).

FIGURE 1.

Expression of Shh on FDCs. A–C, Cryosections of LNs from OVA-stimulated mice were triple-stained with anti-Shh (green fluorescence), anti-FDCs (FDC-M2; red fluorescence), and PNA (blue fluorescence) to identify GCs. D, Detail of the expression of Shh in GCs. Note the expression of Shh on the FDC network (yellow fluorescence). E, Lack of coexpression of Shh (green fluorescence) and B220 (red fluorescence) in GCs. F and G, In primary follicles from nonimmunized mice, only a small number of FDCs (red fluorescence) weakly express Shh (green fluorescence).

FIGURE 1.

Expression of Shh on FDCs. A–C, Cryosections of LNs from OVA-stimulated mice were triple-stained with anti-Shh (green fluorescence), anti-FDCs (FDC-M2; red fluorescence), and PNA (blue fluorescence) to identify GCs. D, Detail of the expression of Shh in GCs. Note the expression of Shh on the FDC network (yellow fluorescence). E, Lack of coexpression of Shh (green fluorescence) and B220 (red fluorescence) in GCs. F and G, In primary follicles from nonimmunized mice, only a small number of FDCs (red fluorescence) weakly express Shh (green fluorescence).

Close modal

The expression of RNAs encoding Shh was assessed by RT-PCR. We found Shh RNA transcripts in FDC-enriched cell populations from secondary lymphoid organs (Fig. 2,A). In contrast, we were unable to detect Shh encoding RNAs in GC B cells (Fig. 2 A).

FIGURE 2.

Expression of Hh receptors in GC cells. A, RT-PCR analysis of the expression of Shh, Ptc, and Smo in FDC-enriched GC cells (lane 1) and isolated GC B cells (lane 2) from murine lymph nodes. H2O served as negative control (lane 3). G3PDH was used as control for sample loading. B, Isolated GC cells were stained with anti-Ptc-FITC and anti-Smo-PE Abs, anti-B220-allophycocyanin mAb and PNA-biotin, and Tricolor-streptavidin. The dot plot represents the expression of Ptc vs Smo on B220+PNAhigh GC B cells. C, GC cells were isolated and stimulated with anti-CD40 mAb, anti-IgM mAb, or LPS. After 4 h, cells were harvested and stained with anti-B220-allophycocyanin mAb, PNA-FITC, and anti-Smo-PE Ab. Bars represent the mean percentage (±SD) of Smo-expressing cells in the B220+PNAhigh GC B cell population from three independent experiments (∗, p ≤ 0.05, by t test).

FIGURE 2.

Expression of Hh receptors in GC cells. A, RT-PCR analysis of the expression of Shh, Ptc, and Smo in FDC-enriched GC cells (lane 1) and isolated GC B cells (lane 2) from murine lymph nodes. H2O served as negative control (lane 3). G3PDH was used as control for sample loading. B, Isolated GC cells were stained with anti-Ptc-FITC and anti-Smo-PE Abs, anti-B220-allophycocyanin mAb and PNA-biotin, and Tricolor-streptavidin. The dot plot represents the expression of Ptc vs Smo on B220+PNAhigh GC B cells. C, GC cells were isolated and stimulated with anti-CD40 mAb, anti-IgM mAb, or LPS. After 4 h, cells were harvested and stained with anti-B220-allophycocyanin mAb, PNA-FITC, and anti-Smo-PE Ab. Bars represent the mean percentage (±SD) of Smo-expressing cells in the B220+PNAhigh GC B cell population from three independent experiments (∗, p ≤ 0.05, by t test).

Close modal

Because FDCs expressed high levels of Shh in GCs, the expression of Ptc and Smo, both components of the Hh receptor, was studied in B cells maturing in GCs. RNAs specific for Ptc and Smo were detected in GC B cells (Fig. 2,A). Flow cytometry revealed that all B220+PNAhigh GC B cells expressed Ptc, the component of Hh receptor that binds Shh, whereas ∼30% coexpressed Smo, the signaling component of Hh receptor (Fig. 2 B). Thus, all GC B cells are capable of binding Hh proteins at their cell surface, and ∼30% are capable of transducing the Hh signal into the cell.

Modulation of the expression of Hh receptors on GC B cells in response to different activating stimuli was also analyzed. After 4 h, anti-CD40 and anti-IgM stimulations significantly increased the proportions of Smo+ GC B cells. The percentage of Smo-expressing B220+PNAhigh cells increased ∼40–50% after CD40 ligation and IgM cross-linking, whereas stimulation with LPS hardly affected the proportion of Smo+ GC B cells (Fig. 2 C). The percentage of Ptc-positive GC B cells did not change significantly after stimulation (data not shown).

We investigated the effects of Shh deprivation on the proliferation and Ab production by GC B cells. For this purpose, GC cells were isolated and cultured for 1, 4, and 7 days in the presence of the steroidal alkaloid cyclopamine or the neutralizing anti-Shh mAb 5E1, both inhibitors of the Hh signaling pathway (40, 43, 44). As previously described (36), these cultures could maintain B cell proliferation for several days, although after 7 days the proliferation was reduced by 50%. Blockade of Hh signaling by the addition of cyclopamine or anti-Shh mAb caused a decrease in the proliferation of GC B cells during the first days of culture, but only slight differences could be detected by day 7 of culture (Fig. 3 A).

FIGURE 3.

Blockade of Shh signaling inhibits proliferation and Ig production by GC B cells. A, GC cells were isolated and cultured alone or in the presence of cyclopamine or anti-Shh mAb. Proliferation was analyzed on culture days 1, 4, and 7. BrdU was added for the last 12 h, and BrdU incorporation to newly synthesized DNA was measured as described in Materials and Methods. Bars represent the mean (±SD) of three independent experiments (∗, p ≤ 0.05, by t test). B, GC cells were cultured with either medium alone or cyclopamine. Levels of Ig isotypes in the supernatants after 7 days of culture were determined by ELISA. The results are presented as the mean (±SD) of quadruplicate data (∗, p ≤ 0.05; ∗∗∗, p ≤ 0.001 (by t test)). The results shown are representative of three or four independent experiments. □, Control; ▪, cyclopamine.

FIGURE 3.

Blockade of Shh signaling inhibits proliferation and Ig production by GC B cells. A, GC cells were isolated and cultured alone or in the presence of cyclopamine or anti-Shh mAb. Proliferation was analyzed on culture days 1, 4, and 7. BrdU was added for the last 12 h, and BrdU incorporation to newly synthesized DNA was measured as described in Materials and Methods. Bars represent the mean (±SD) of three independent experiments (∗, p ≤ 0.05, by t test). B, GC cells were cultured with either medium alone or cyclopamine. Levels of Ig isotypes in the supernatants after 7 days of culture were determined by ELISA. The results are presented as the mean (±SD) of quadruplicate data (∗, p ≤ 0.05; ∗∗∗, p ≤ 0.001 (by t test)). The results shown are representative of three or four independent experiments. □, Control; ▪, cyclopamine.

Close modal

When GC cells were cultured in the presence or the absence of cyclopamine for 7 days, the supernatants were collected, and the Ab titers were determined. Blockade of the Hh signaling pathway differentially affected the ability of GC B cells to produce different Ig isotypes. The addition of cyclopamine significantly reduced IgM, IgG1, and IgG2b titers by 20–30%, whereas IgG2a and IgG3 secretion was not affected by cyclopamine (Fig. 3 B).

Given that Shh has been described as an antiapoptotic factor for several cell types (29, 45, 46, 47, 48, 49), we decided to examine whether Shh also affected the survival of GC B cells. Isolated GC cells were cultured in the presence or the absence of Hh signaling inhibitors, and the proportion of annexin V-positive dying cells was assessed in the B220+PNAhigh GC B cell population. After 12 h, inhibition of Hh signaling significantly increased the proportion of apoptotic GC B cells. As shown in Fig. 4, the addition of anti-Shh mAb and cyclopamine increased the percentages of annexin V-positive GC B cells by ∼45 and 75%, respectively. These results indicate that endogenous Shh produced by FDCs is a survival stimulus for GC B cells.

FIGURE 4.

Inhibition of Shh signaling reduces GC B cell survival. Isolated GC cells were cultured in the absence or the presence of Hh signaling inhibitors, cyclopamine and anti-Shh mAb. After 12 h, the proportion of apoptotic cells (annexin V-positive, propidium iodide-negative) was analyzed in the B220+PNAhigh GC B cell population. Data are the mean (±SD) from three independent experiments (∗, p ≤ 0.05; ∗∗, p ≤ 0.01 (by t test)).

FIGURE 4.

Inhibition of Shh signaling reduces GC B cell survival. Isolated GC cells were cultured in the absence or the presence of Hh signaling inhibitors, cyclopamine and anti-Shh mAb. After 12 h, the proportion of apoptotic cells (annexin V-positive, propidium iodide-negative) was analyzed in the B220+PNAhigh GC B cell population. Data are the mean (±SD) from three independent experiments (∗, p ≤ 0.05; ∗∗, p ≤ 0.01 (by t test)).

Close modal

GC B cells rapidly undergo apoptosis in vitro, and this process is enhanced after Fas ligation (33, 50, 51, 52). To investigate whether exogenous Shh has the ability to maintain the survival of GC B cells, we cultured isolated GC B cells in the presence of anti-CD95 mAb and different concentrations of Shh. After 12 h, ∼30% of B220+PNAhigh cells were annexin V-positive dying cells. The proportion of apoptotic cells increased after ligation of Fas, but this effect was counteracted by Shh. The apoptosis-inhibiting effect of Shh was concentration dependent and maximal at 100 ng/ml (Fig. 5). In addition, the survival effect of the highest dose of Shh was similar to that from other apoptosis-inhibiting stimuli, such as anti-CD40 and anti-IgM cross-linkings (Fig. 5). Hence, Hh signaling plays a role in rescue from CD95-induced apoptosis.

FIGURE 5.

Shh rescues GC B cells from Fas-induced apoptosis. GC B cells were isolated and cultured with anti-CD95 mAb in the absence or the presence of recombinant Shh protein (0.01–100 ng/ml), anti-CD40 mAb, or anti-IgM Ab. After 12 h, the proportion of apoptotic cells (annexin V-positive, propidium iodide-negative) was analyzed in the B220+PNAhigh GC B cell population. Data are the mean (±SD) from three to four independent experiments.

FIGURE 5.

Shh rescues GC B cells from Fas-induced apoptosis. GC B cells were isolated and cultured with anti-CD95 mAb in the absence or the presence of recombinant Shh protein (0.01–100 ng/ml), anti-CD40 mAb, or anti-IgM Ab. After 12 h, the proportion of apoptotic cells (annexin V-positive, propidium iodide-negative) was analyzed in the B220+PNAhigh GC B cell population. Data are the mean (±SD) from three to four independent experiments.

Close modal

In this study we report that the Hh signaling pathway plays a role in the Ag-driven B cell differentiation that occurs in GCs. Shh is strongly expressed by the FDC network found in GCs, whereas in the primary follicles the expression of Shh is much weaker and is restricted to a few FDCs. These data suggest that up-regulation of Shh production by FDCs is dependent on antigenic stimulus and interaction with Ag-activated B cells. During the GC reaction, Ag-activated B cells move into the FDC network and replace the primary resting B cells that are initially located within the FDC reticulum of the primary follicles (32, 53). Up-regulation of the expression of several surface cell markers, i.e., FDC-M1, FcεRII/CD23, FcγRII/CD32, VCAM1/CD106, MAdCAM-1 (54, 55, 56, 57), and some soluble factors such as IL-6 and FDC-SP (38, 58), is a common feature of the development of the FDC network after immunization and reflects the involvement of those molecules in the maturational events associated with GCs. These membrane Ags and secreted proteins constitute indicators of FDC maturation and activation, and Shh could now be considered a new member of this group.

The fact that GC B cells express the two components of the Hh receptor, Ptc and Smo, indicates that GC B cells are cell targets for Shh produced by FDCs. Furthermore, the expression of Smo, the Hh signal transducing receptor, is rapidly up-regulated upon GC B cell activation with anti-IgM and anti-CD40 mAbs (which mimic the physiological signals that B cells receive in vivo). This up-regulation of Smo expression after GC B cell stimulation suggests the existence of a direct link among the BCR, CD40, and Hh signaling pathways.

We show that the main role of FDC-derived Shh is to act as a survival factor for GC B cells, because the proportion of apoptotic GC B cells increases after Hh signaling inhibition, and exogenous Shh addition rescues GC B cells from Fas-induced apoptosis. Our results also show that proliferation and Ig secretion by GC B cells are reduced when Hh signaling is inhibited, but these effects are probably the consequence of the decreased GC B cell survival observed. Antiapoptotic effects of Shh have been also demonstrated during development of the nervous system (45), teeth (59), and external genitalia (46), as well as in somite cells (48), keratinocytes (49), thymocytes (60), T lymphocytes (29), and certain neuron populations (47). In GCs, three types of stimuli seem to prevent apoptosis in GC B cells: ligation of the BCR, ligation of CD40, and unknown signals delivered by FDCs (33). All these stimuli have been described to sustain the expression of the long isoform of cellular FLIPL (cFLIPL), which inhibits the Fas-induced activation of caspase 8 (33, 50, 52). When GC B cells are isolated and removed from their microenvironment, cFLIPL is quickly degraded, resulting in the activation of caspase 8 and, subsequently, caspase 3. In contrast, interaction with FDCs maintains high levels of expression of cFLIPL, preventing activation of caspase 8 and protecting these cells against Fas-induced cell death (33, 50, 52). The FDC-derived, antiapoptotic signal acts independently of CD40-mediated signals, BCR, or adhesion molecules, such as ICAM-1 or VCAM (51). It is tempting, therefore, to speculate that Shh could be the FDC-produced factor involved in the maintenance of cFLIPL expression and the prevention of Fas-induced apoptosis in high affinity GC B cells while they are trapped in the FDC network.

Taken together, the current data provide evidence that the Hh signaling pathway is involved in GC reactions. Shh seems to be an FDC-derived antiapoptotic signal contributing to the prevention of B cell death in the GC in conjunction with BCR- and CD40-delivered survival signals. Additionally, upon CD40 and BCR ligation, cell surface Smo expression on GC B cells is up-regulated, thereby increasing the ability of these cells to respond to Shh.

We thank Curis for providing human Shh protein, and Dr. William Gaffield for the gift of the cyclopamine used in these studies.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1

This work was supported by Grants CAM08.3/0018.1/2001 and CAM08.1/0038.1/2003 from the Comunidad Autónoma de Madrid, and PM99-0060, BMC2001-2025, and BMC2003-01901. T.Cr. and S.V.O. are supported by the Wellcome Trust. This work was also supported by Acciones Integradas Hispano-Británicas.

4

Abbreviations used in this paper: Hh, Hedgehog; cFLIPL, cellular FLIPL; FDC, follicular dendritic cell; GC, germinal center; LN, lymph node; PNA, peanut agglutinin; Ptc, Patched; Shh, Sonic Hh; Smo, Smoothened.

1
Ingham, P. W., A. P. McMahon.
2001
. Hedgehog signaling in animal development: paradigms and principles.
Genes Dev.
15
:
3059
.
2
McMahon, A. P., P. W. Ingham, C. J. Tabin.
2003
. Developmental roles and clinical significance of Hedgehog signaling.
Curr. Top. Dev. Biol.
53
:
1
.
3
Nusslein-Volhard, C., E. Wieschaus.
1980
. Mutations affecting segment number and polarity in Drosophila.
Nature
287
:
795
.
4
Bumcrot, D. A., R. Takada, A. P. McMahon.
1995
. Proteolytic processing yields two secreted forms of Sonic Hedgehog.
Mol. Cell. Biol.
15
:
2294
.
5
Lee, J. J., S. C. Ekker, D. P. von Kessler, J. A. Porter, B. I. Sun, P. A. Beachy.
1994
. Autoproteolysis in Hedgehog protein biogenesis.
Science
266
:
1528
.
6
Ingham, P. W..
2001
. Hedgehog signaling: a tale of two lipids.
Science
294
:
1879
.
7
Porter, J. A., D. P. von Kessler, S. C. Ekker, K. E. Young, J. J. Lee, K. Moses, P. A. Beachy.
1995
. The product of Hedgehog autoproteolytic cleavage active in local and long-range signalling.
Nature
374
:
363
.
8
Jeong, J., A. P. McMahon.
2002
. Cholesterol modification of Hedgehog family proteins.
J. Clin. Invest.
110
:
591
.
9
Caspary, T., M. J. Garcia-Garcia, D. Huangfu, J. T. Eggenschwiler, M. R. Wyler, A. S. Rakeman, H. L. Alcorn, K. V. Anderson.
2002
. Mouse Dispatched homolog1 is required for long-range, but not juxtacrine, Hh signaling.
Curr. Biol.
12
:
1628
.
10
Kawakami, T., T. Kawcak, Y. J. Li, W. Zhang, Y. Hu, P. T. Chuang.
2002
. Mouse dispatched mutants fail to distribute Hedgehog proteins and are defective in Hedgehog signaling.
Development
129
:
5753
.
11
Zeng, X., J. A. Goetz, L. M. Suber, W. J. Scott, Jr, C. M. Schreiner, D. J. Robbins.
2001
. A freely diffusible form of Sonic Hedgehog mediates long-range signalling.
Nature
411
:
716
.
12
Johnson, R. L., C. Tabin.
1995
. The long and short of Hedgehog signaling.
Cell
81
:
313
.
13
Chuang, P. T., T. B. Kornberg.
2000
. On the range of Hedgehog signaling.
Curr. Opin. Genet. Dev.
10
:
515
.
14
Gritli-Linde, A., P. Lewis, A. P. McMahon, A. Linde.
2001
. The whereabouts of a morphogen: direct evidence for short- and graded long-range activity of Hedgehog signaling peptides.
Dev. Biol.
236
:
364
.
15
Nybakken, K., N. Perrimon.
2002
. Hedgehog signal transduction: recent findings.
Curr. Opin. Genet. Dev.
12
:
503
.
16
Chen, J. K., J. Taipale, K. E. Young, T. Maiti, P. A. Beachy.
2002
. Small molecule modulation of Smoothened activity.
Proc. Natl. Acad. Sci. USA
99
:
14071
.
17
Frank-Kamenetsky, M., X. M. Zhang, S. Bottega, O. Guicherit, H. Wichterle, H. Dudek, D. Bumcrot, F. Y. Wang, S. Jones, J. Shulok, et al
2002
. Small-molecule modulators of Hedgehog signaling: identification and characterization of Smoothened agonists and antagonists.
J. Biol.
1
:
10
.
18
Strutt, H., C. Thomas, Y. Nakano, D. Stark, B. Neave, A. M. Taylor, P. W. Ingham.
2001
. Mutations in the sterol-sensing domain of Patched suggest a role for vesicular trafficking in Smoothened regulation.
Curr. Biol.
11
:
608
.
19
Martin, V., G. Carrillo, C. Torroja, I. Guerrero.
2001
. The sterol-sensing domain of Patched protein seems to control Smoothened activity through Patched vesicular trafficking.
Curr. Biol.
11
:
601
.
20
Mullor, J. L., P. Sanchez, A. R. Altaba.
2002
. Pathways and consequences: Hedgehog signaling in human disease.
Trends Cell Biol.
12
:
562
.
21
Ruiz i Altaba, A..
1999
. Gli proteins encode context-dependent positive and negative functions: implications for development and disease.
Development
126
:
3205
.
22
Koebernick, K., T. Pieler.
2002
. Gli-type zinc finger proteins as bipotential transducers of Hedgehog signaling.
Differentiation
70
:
69
.
23
Bhardwaj, G., B. Murdoch, D. Wu, D. P. Baker, K. P. Williams, K. Chadwick, L. E. Ling, F. N. Karanu, M. Bhatia.
2001
. Sonic Hedgehog induces the proliferation of primitive human hematopoietic cells via BMP regulation.
Nat. Immunol.
2
:
172
.
24
Detmer, K., A. N. Walker, T. M. Jenkins, T. A. Steele, H. Dannawi.
2000
. Erythroid differentiation in vitro is blocked by cyclopamine, an inhibitor of Hedgehog signaling.
Blood Cells Mol. Dis.
26
:
360
.
25
Outram, S. V., A. Varas, C. V. Pepicelli, T. Crompton.
2000
. Hedgehog signaling regulates differentiation from double-negative to double-positive thymocyte.
Immunity
13
:
187
.
26
Sacedon, R., A. Varas, C. Hernandez-Lopez, C. Gutierrez-deFrias, T. Crompton, A. G. Zapata, A. Vicente.
2003
. Expression of Hedgehog proteins in the human thymus.
J. Histochem. Cytochem.
51
:
1557
.
27
Varas, A., A. L. Hager-Theodorides, R. Sacedon, A. Vicente, A. G. Zapata, T. Crompton.
2003
. The role of morphogens in T-cell development.
Trends Immunol.
24
:
197
.
28
Shah, D. K., A. L. Hager-Theodorides, S. V. Outram, S. E. Ross, A. Varas, T. Crompton.
2004
. Reduced thymocyte development in Sonic Hedgehog knockout embryos.
J. Immunol.
172
:
2296
.
29
Lowrey, J. A., G. A. Stewart, S. Lindey, G. F. Hoyne, M. J. Dallman, S. E. Howie, J. R. Lamb.
2002
. Sonic Hedgehog promotes cell cycle progression in activated peripheral CD4+ T lymphocytes.
J. Immunol.
169
:
1869
.
30
Stewart, G. A., J. A. Lowrey, S. J. Wakelin, P. M. Fitch, S. Lindey, M. J. Dallman, J. R. Lamb, S. E. Howie.
2002
. Sonic Hedgehog signaling modulates activation of and cytokine production by human peripheral CD4+ T cells.
J. Immunol.
169
:
5451
.
31
MacLennan, I. C..
1994
. Germinal centers.
Annu. Rev. Immunol.
12
:
117
.
32
Kosco-Vilbois, M. H., J. Y. Bonnefoy, Y. Chvatchko.
1997
. The physiology of murine germinal center reactions.
Immunol. Rev.
156
:
127
.
33
van Eijk, M., T. Defrance, A. Hennino, C. de Groot.
2001
. Death-receptor contribution to the germinal-center reaction.
Trends Immunol.
22
:
677
.
34
Lindhout, E., G. Koopman, S. T. Pals, C. de Groot.
1997
. Triple check for antigen specificity of B cells during germinal centre reactions.
Immunol. Today
18
:
573
.
35
Zhang, X., S. Sun, I. Hwang, D. F. Tough, J. Sprent.
1998
. Potent and selective stimulation of memory-phenotype CD8+ T cells in vivo by IL-15.
Immunity
8
:
591
.
36
Kosco, M. H., E. Pflugfelder, D. Gray.
1992
. Follicular dendritic cell-dependent adhesion and proliferation of B cells in vitro.
J. Immunol.
148
:
2331
.
37
Poudrier, J., P. Graber, S. Herren, D. Gretener, G. Elson, C. Berney, J. F. Gauchat, M. H. Kosco-Vilbois.
1999
. A soluble form of IL-13 receptor α1 promotes IgG2a and IgG2b production by murine germinal center B cells.
J. Immunol.
163
:
1153
.
38
Kopf, M., S. Herren, M. V. Wiles, M. B. Pepys, M. H. Kosco-Vilbois.
1998
. Interleukin 6 influences germinal center development and antibody production via a contribution of C3 complement component.
J. Exp. Med.
188
:
1895
.
39
Varas, A., E. Jimenez, R. Sacedon, M. Rodriguez-Mahou, E. Maroto, A. G. Zapata, A. Vicente.
2000
. Analysis of the human neonatal thymus: evidence for a transient thymic involution.
J. Immunol.
164
:
6260
.
40
Ericson, J., S. Morton, A. Kawakami, H. Roelink, T. M. Jessell.
1996
. Two critical periods of Sonic Hedgehog signaling required for the specification of motor neuron identity.
Cell
87
:
661
.
41
Pepinsky, R. B., C. Zeng, D. Wen, P. Rayhorn, D. P. Baker, K. P. Williams, S. A. Bixler, C. M. Ambrose, E. A. Garber, K. Miatkowski, et al
1998
. Identification of a palmitic acid-modified form of human Sonic Hedgehog.
J. Biol. Chem.
273
:
14037
.
42
Ferguson, S. E., S. Han, G. Kelsoe, C. B. Thompson.
1996
. CD28 is required for germinal center formation.
J. Immunol.
156
:
4576
.
43
Incardona, J. P., W. Gaffield, R. P. Kapur, H. Roelink.
1998
. The teratogenic Veratrum alkaloid cyclopamine inhibits Sonic Hedgehog signal transduction.
Development
125
:
3553
.
44
Chen, J. K., J. Taipale, M. K. Cooper, P. A. Beachy.
2002
. Inhibition of Hedgehog signaling by direct binding of cyclopamine to Smoothened.
Genes Dev.
16
:
2743
.
45
Charrier, J. B., F. Lapointe, N. M. Le Douarin, M. A. Teillet.
2001
. Anti-apoptotic role of Sonic Hedgehog protein at the early stages of nervous system organogenesis.
Development
128
:
4011
.
46
Perriton, C. L., N. Powles, C. Chiang, M. K. Maconochie, M. J. Cohn.
2002
. Sonic Hedgehog signaling from the urethral epithelium controls external genital development.
Dev. Biol.
247
:
26
.
47
Miao, N., M. Wang, J. A. Ott, J. S. D’Alessandro, T. M. Woolf, D. A. Bumcrot, N. K. Mahanthappa, K. Pang.
1997
. Sonic Hedgehog promotes the survival of specific CNS neuron populations and protects these cells from toxic insult in vitro.
J. Neurosci.
17
:
5891
.
48
Cann, G. M., J. W. Lee, F. E. Stockdale.
1999
. Sonic Hedgehog enhances somite cell viability and formation of primary slow muscle fibers in avian segmented mesoderm.
Anat. Embryol.
200
:
239
.
49
Bigelow, R. L., N. S. Chari, A. B. Unden, K. B. Spurgers, S. Lee, D. R. Roop, R. Toftgard, T. J. McDonnell.
2004
. Transcriptional regulation of bcl-2 mediated by the Sonic Hedgehog signaling pathway through gli-1.
J. Biol. Chem.
279
:
1197
.
50
Hennino, A., M. Berard, P. H. Krammer, T. Defrance.
2001
. FLICE-inhibitory protein is a key regulator of germinal center B cell apoptosis.
J. Exp. Med.
193
:
447
.
51
Koopman, G., R. M. Keehnen, E. Lindhout, D. F. Zhou, C. de Groot, S. T. Pals.
1997
. Germinal center B cells rescued from apoptosis by CD40 ligation or attachment to follicular dendritic cells, but not by engagement of surface immunoglobulin or adhesion receptors, become resistant to CD95-induced apoptosis.
Eur. J. Immunol.
27
:
1
.
52
van Eijk, M., J. P. Medema, C. de Groot.
2001
. Cutting edge: cellular Fas-associated death domain-like IL-1-converting enzyme-inhibitory protein protects germinal center B cells from apoptosis during germinal center reactions.
J. Immunol.
166
:
6473
.
53
Camacho, S. A., M. H. Kosco-Vilbois, C. Berek.
1998
. The dynamic structure of the germinal center.
Immunol. Today
19
:
511
.
54
Balogh, P., Y. Aydar, J. G. Tew, A. K. Szakal.
2002
. Appearance and phenotype of murine follicular dendritic cells expressing VCAM-1.
Anat. Rec.
268
:
160
.
55
Martinez-Pomares, L., M. Kosco-Vilbois, E. Darley, P. Tree, S. Herren, J. Y. Bonnefoy, S. Gordon.
1996
. Fc chimeric protein containing the cysteine-rich domain of the murine mannose receptor binds to macrophages from splenic marginal zone and lymph node subcapsular sinus and to germinal centers.
J. Exp. Med.
184
:
1927
.
56
Maeda, K., G. F. Burton, D. A. Padgett, D. H. Conrad, T. F. Huff, A. Masuda, A. K. Szakal, J. G. Tew.
1992
. Murine follicular dendritic cells and low affinity Fc receptors for IgE (FcεRII).
J. Immunol.
148
:
2340
.
57
Qin, D., J. Wu, K. A. Vora, J. V. Ravetch, A. K. Szakal, T. Manser, J. G. Tew.
2000
. Fcγ receptor IIB on follicular dendritic cells regulates the B cell recall response.
J. Immunol.
164
:
6268
.
58
Marshall, A. J., Q. Du, K. E. Draves, Y. Shikishima, K. T. HayGlass, E. A. Clark.
2002
. FDC-SP, a novel secreted protein expressed by follicular dendritic cells.
J. Immunol.
169
:
2381
.
59
Cobourne, M. T., Z. Hardcastle, P. T. Sharpe.
2001
. Sonic Hedgehog regulates epithelial proliferation and cell survival in the developing tooth germ.
J. Dent. Res.
80
:
1974
.
60
Gutierrez-Frias, C., R. Sacedon, C. Hernandez-Lopez, T. Cejalvo, T. Crompton, A. G. Zapata, A. Varas, A. Vicente.
2004
. Sonic Hedgehog regulates early human thymocyte differentiation by counteracting the IL-7-induced development of CD34+ precursor cells.
J. Immunol.
173
:
5046
.